Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study
Top Cited Papers
- 1 August 2007
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 370 (9585) , 389-397
- https://doi.org/10.1016/s0140-6736(07)61194-5
Abstract
No abstract availableKeywords
Funding Information
- Bayer Schering
This publication has 22 references indexed in Scilit:
- Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patientsAnnals of Neurology, 2006
- Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesionAnnals of Neurology, 2004
- Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosisMultiple Sclerosis Journal, 2001
- Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple SclerosisNew England Journal of Medicine, 2000
- A Novel Bioassay for the Determination of Neutralizing Antibodies to IFNβ1bJournal of Interferon & Cytokine Research, 1998
- Axonal Transection in the Lesions of Multiple SclerosisNew England Journal of Medicine, 1998
- Validation of the Functional Assessment of Multiple Sclerosis quality of life instrumentNeurology, 1996
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983